Emergent Biosolutions announced a $51 million contract from BARDA for the development of a new anthrax vaccine utilising their protective antigen rPA. This antigen stimulates a protective immune-response that neutralises the anthrax toxins – which has long been an element of concern.

Meanwhile Cleveland BioLabs snagged a $45 million contract from CBMS for their CBLB502 radiation countermeasure. $14.8 million of this is for advanced development of the countermeasure while the remained is for purchase, after FDA approval, of the necessary dosage for US Forces.

  • Follow us on Twitter
  • Subscribe to CBRNe news

View articles by date

 
cbrne